Correlation Between Apollomics and ZyVersa Therapeutics

Can any of the company-specific risk be diversified away by investing in both Apollomics and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apollomics and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apollomics Class A and ZyVersa Therapeutics, you can compare the effects of market volatilities on Apollomics and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apollomics with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apollomics and ZyVersa Therapeutics.

Diversification Opportunities for Apollomics and ZyVersa Therapeutics

0.24

Correlation Coefficient

Apollomics  ZyVersa Therapeutics

Modest diversification

The 3 months correlation between Apollomics and ZyVersa is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Apollomics Class A and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Apollomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apollomics Class A are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Apollomics i.e., Apollomics and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between Apollomics and ZyVersa Therapeutics

Given the investment horizon of 90 days Apollomics Class A is expected to generate 1.03 times more return on investment than ZyVersa Therapeutics. However, Apollomics is 1.03 times more volatile than ZyVersa Therapeutics. It trades about -0.04 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  1,013  in Apollomics Class A on December 30, 2024 and sell it today you would lose (252.00) from holding Apollomics Class A or give up 24.88% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Apollomics Class A  vs.  ZyVersa Therapeutics

Apollomics Class A

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apollomics Class A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

ZyVersa Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Apollomics and ZyVersa Therapeutics

The main advantage of trading using opposite Apollomics and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apollomics position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.

The idea behind Apollomics Class A and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.